Careview

What Careview does

Careview Corporation is a Philippines-based, SEC-registered private healthcare company founded in 2017 that operates the largest network of PET/CT diagnostic imaging centers in the country, with eight operational locations across Metro Manila, Pampanga, and Batangas. The company provides molecular imaging services for cancer diagnosis, staging, treatment planning, and monitoring, including FDG-PET/CT (general oncology), FPSMA-PET/CT (prostate cancer), FBB/Neuraceq PET (Alzheimer's and dementia), and LuPSMA-PET/CT Theranostics for metastatic castration-resistant prostate cancer, complemented by chemotherapy at select centers. The technology stack centers on PET/CT hybrid imaging, which combines metabolic and structural scanning to detect malignant lesions at the molecular level before anatomical changes are visible, achieving reported 90-95% diagnostic accuracy; Careview operates as the exclusive domestic distributor of Khealth Corporation's radiopharmaceuticals, including sole supply rights for FBB and LuPSMA in the Philippines.

Careview runs a direct-to-patient, sales-led go-to-market model. Patients access services through the Klinika Pro online portal, the Carecall reservation hotline, walk-ins at partner hospitals (NKTI, AUFMC, MMMC, Centuria Medical Makati, BGC Cancer Center, SM Valenzuela, Manila), and physician referrals from co-located hospital partners. Centers operate 6am-6pm Monday through Saturday. The company accepts government guarantee letters from DSWD and PCSO, alongside credit card, Gcash, and bank transfer, with dedicated Patient Support Coordinators facilitating financial assistance processing for underinsured patients. Cumulative volume since 2015 includes 22,000+ FDG-PET/CT scans and 800+ FPSMA-PET/CT scans.

Revenue mechanics are fee-for-service per imaging procedure and per chemotherapy/theranostics treatment course. Pricing is not publicly disclosed. The company reports a headcount band of 1-10, which almost certainly understates actual clinical, technical, and administrative staffing across eight physical sites. No funding rounds, institutional investors, or management team are disclosed in the available data. The addressable market is the Philippine cancer and neurology patient population, with geographic concentration in Luzon and unmet demand in Visayas and Mindanao representing potential expansion territory.

Name

Careview

Legal name

Careview Corporation

Website

https://careviewcorp.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Careview Corporation operates the largest PET/CT imaging network in the Philippines, with eight centers providing cancer diagnosis, staging, and theranostics services to oncology, prostate cancer, and neurology patients under an exclusive radiopharmaceutical supply partnership with Khealth Corporation.

Ownership category

akta.pro rank

Product category

Cancer Diagnostic Imaging Services

NAICS

Diagnostic Imaging Centers (621512), Offices of Physicians (62111)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)

akta.pro primary industry

Advanced Imaging & Specialty Radiology Centers (PET/CT, Nuclear Medicine, Interventional Radiology) (HLAFAKAB)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

Keywords

• Cancer diagnostic imaging
• PET/CT molecular imaging
• Radiopharmaceuticals distribution
• Theranostics treatment
• Oncology imaging services

Headquarters

HQ city

Makati

HQ country

Philippines

HQ region

Asia

Offices7 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Infrastructure

Revenue model

1. PET/CT Diagnostic Imaging Services: Fee-for-service medical imaging revenue generated from PET/CT scan procedures. Services include FDG-PET/CT, FPSMA-PET/CT, FBB-PET/CT, and LuPSMA-PET/CT scans for cancer diagnosis, staging, and monitoring. Volume-based revenue dependent on patient throughput across 8 operational centers.
2. Chemotherapy Treatment Services: Personalized chemotherapy treatment services provided in a supportive environment, managing side effects and maintaining quality of life for cancer patients.
3. Financial Assistance Processing Services: Patient Support Coordinators assist in processing financial assistance from government agencies (DSWD, PCSO), facilitating access to services for patients with government-funded payment arrangements.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Careview operates 8 PET/CT molecular imaging centers across the Philippines providing cancer diagnostic imaging services including FDG-PET/CT, FPSMA-PET/CT, FBB-PET/CT, and LuPSMA-PET/CT theranostics, alongside personalized chemotherapy treatments. As the exclusive Philippine distributor of Khealth Corporation's radiopharmaceuticals (FDG, FPSMA, FBB, LuPSMA), Careview delivers end-to-end oncology imaging and therapy supported by Carecall reservation services and the Klinika Pro patient portal.

Product overview

Careview operates a network of 8 PET/CT diagnostic imaging centers across the Philippines offering molecular imaging services. The core product portfolio includes FDG-PET/CT for detecting metabolically active malignant lesions, FPSMA-PET/CT for prostate cancer detection, FBB for Alzheimer's Disease diagnosis via amyloid plaque evaluation, and LuPSMA-PET/CT for theranostic treatment of metastatic prostate cancer. These imaging services are complemented by chemotherapy treatments at select centers. The Klinika Pro patient portal provides patients secure access to their treatment results online. Together, these services form a comprehensive cancer diagnosis and therapy ecosystem spanning detection, diagnosis, treatment, and patient access.

Differentiator

Problem solved

Functional benefit

Brands

• Klinika Pro: Patient portal for accessing treatment results securely anytime, anywhere

Products and services

• FDG-PET/CT A Nuclear Medicine imaging procedure that detects metabolically active malignant lesions through PET combined with CT structural imaging, enabling non-invasive diagnosis and staging for optimal management of cancer patients. Achieves 90-95% accuracy in detecting, evaluating, and monitoring cancers.
• FPSMA-PET/CT A PSMA PET scan with greater sensitivity for detecting prostate cancer metastases sooner, named a top medical innovation by Cleveland Clinic in 2022. Enables clinicians to detect metastases earlier and make treatment decisions earlier. More than 800 patients scanned since 2019.
• FBB-PET (Neuraceq) Imaging A PET imaging procedure used for the evaluation of beta amyloid neuritic plaque density, providing differentiation between Alzheimer's Disease and other forms of Dementia. Careview supplies FBB under exclusive rights from Khealth Corporation, the only manufacturer in the Philippines with those rights.
• LuPSMA-PET/CT Theranostics A theranostics approach paired with FPSMA-PET/CT that uses LuPSMA treatment for metastatic castration-resistant prostate cancer (mCRPC), leveraging PSMA specificity to target prostate cancer cells.
• Chemotherapy Treatment Personalized chemotherapy treatments provided in a supportive environment, focused on treating cancer and managing side effects while maintaining patient quality of life. Available at select Careview centers including BGC Cancer Center.
• Klinika Pro Patient Portal An online patient portal enabling patients to securely access their treatment results anytime and anywhere.

Quantifiable outcome

• 90-95% accuracy in detecting, evaluating, and monitoring cancers
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

One partnership is on record.

• Khealth CorporationcoreStrategic or Co-development PartnerCAREVIEW is the exclusive distributor of Khealth radiopharmaceuticals including FDG, FPSMA, FBB (Neuraceq), and LuPSMA. Khealth is the leading manufacturer of PET tracers and the only commercial manufacturer of FBB and LuPSMA in the Philippines. This partnership ensures guaranteed provision of specialized radiopharmaceuticals required for PET/CT imaging and theranostics treatments.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Bumrungrad International Hospital: Bangkok-based international hospital with a comprehensive cancer center offering PET/CT and theranostics, including PSMA-targeted imaging. Comparable advanced oncology diagnostics footprint across a different Southeast Asian geography.
• Apollo Hospitals: India's largest multi-specialty hospital chain with PET/CT and comprehensive cancer care including theranostics. Comparable vertically integrated diagnostic-imaging + oncology model operating in another emerging Asian market.
• Bangkok Hospital: Thailand's largest private hospital network with established PET/CT imaging and oncology programs. Comparable to Careview in scale of molecular imaging services and cancer treatment positioning within Southeast Asia.

Broad incumbents

• RadNet: Largest US outpatient imaging provider with diagnostic centers including PET/CT and related oncology imaging. Representative incumbent imaging-services business model at substantially greater scale than Careview's Philippine network.

Direct peers

• Asian Hospital and Medical Center: Philippine tertiary hospital operating an oncology service line and advanced imaging. Direct competitor for Metro Manila oncology referrals that could otherwise route to Careview's PET/CT network.
• The Medical City: Philippine tertiary hospital with a multi-specialty cancer center offering diagnostic imaging, chemotherapy, and multidisciplinary oncology care. Overlaps with Careview's Manila-area cancer diagnosis and treatment offering.
• Makati Medical Center: Major Makati-based private hospital with oncology and advanced diagnostic imaging departments. Competes with Careview's Centuria Medical Makati center for cancer-related imaging and therapy patients in the same geography.
• St. Luke's Medical Center: Philippine tertiary hospital system operating the St. Luke's Cancer Institute with PET/CT imaging and medical oncology services. Directly competes with Careview for cancer diagnosis and treatment volumes in Metro Manila.
• Manila Doctors Hospital: Manila-based private hospital offering oncology consultations, diagnostic imaging, and chemotherapy. Comparable to Careview in combining cancer diagnosis and treatment within a single hospital setting in the same metro market.

Others

• Khealth Corporation: Philippine manufacturer of PET radiopharmaceuticals (FDG, FPSMA, FBB, LuPSMA) and Careview's exclusive distribution partner. An enabling supplier that provides the proprietary inputs underpinning Careview's PET/CT and theranostics service line.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/CareviewCorporation
• LinkedInlinkedin.com/company/careview

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Careview